Sino Biopharmaceutical (HKG:1177) recorded a rise in attributable profit in the first half of 2025 to 3.39 billion yuan from 3.02 billion yuan in the year-ago period, a Monday Hong Kong bourse filing said.

Earnings per share were 0.188 yuan in the half year, up from 0.1639 yuan in the corresponding period of the last fiscal year.

The biopharmaceutical company's revenue from continuing operations rose 11% to 17.6 billion yuan in the interim period from 15.9 billion yuan a year prior.

The firm declared an interim dividend of HK$0.05 per share for the period, payable Sept. 23 to shareholders of record on Sept. 3.